• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Natera Inc (NQ: NTRA )

    151.11 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Natera Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Natera Reports Third Quarter 2024 Financial Results
    From Natera, Inc.
    Via Business Wire
    Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
    From Natera, Inc.
    Via Business Wire
    Natera to Participate in Upcoming Investor Conferences
    From Natera, Inc.
    Via Business Wire
    Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
    Via Investor Brand Network
    Natera to Report its Third Quarter 2024 Results on November 12, 2024
    From Natera, Inc.
    Via Business Wire
    Natera to Present New Renasight Data at ASN Kidney Week 2024
    From Natera, Inc.
    Via Business Wire
    Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
    From Natera, Inc.
    Via Business Wire
    Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
    From Natera, Inc.
    Via Business Wire
    First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
    From Natera, Inc.
    Via Business Wire
    Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
    From Natera, Inc.
    Via Business Wire
    Natera Reports Second Quarter 2024 Financial Results
    From Natera, Inc.
    Via Business Wire
    Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Natera, Inc.
    Via Business Wire
    Natera to Report its Second Quarter 2024 Results on August 8, 2024
    From Natera, Inc.
    Via Business Wire
    New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
    From Natera, Inc.
    Via Business Wire
    Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
    From Natera, Inc.
    Via Business Wire
    Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
    From Natera, Inc.
    Via Business Wire
    Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
    Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
    Via MarketBeat
    Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
    From Natera, Inc.
    Via Business Wire
    Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Natera, Inc.
    Via Business Wire
    Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
    From Natera, Inc.
    Via Business Wire
    Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
    From Natera, Inc.
    Via Business Wire
    Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
    From Natera, Inc.
    Via Business Wire
    NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Natera Reports First Quarter 2024 Financial Results
    From Natera, Inc.
    Via Business Wire
    New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
    From Natera, Inc.
    Via Business Wire
    Natera to Report its First Quarter 2024 Results on May 9
    From Natera, Inc.
    Via Business Wire
    Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
    From Natera, Inc.
    Via Business Wire
    Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
    From Natera, Inc.
    Via Business Wire
    Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
    From Natera, Inc.
    Via Business Wire
    Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
    From Natera, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.